NCT07362017
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Recruiting
PHASE3Ages 18–65InterventionalTreatmentVanda Pharmaceuticals
~300 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:Ponesimod
At a glance
Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability of ponesimod as measured by reporting of adverse events (AEs)
Measured over Through study completion, approximately 1 year
Conditions
Where it's being run
4 sites across 4 statesArizona1
California1
New York1
Washington1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male and female subjects aged 18-65 years, inclusive
BMI \>18 and \<40
Minimum affected BSA of 10%
PASI score ≥ 12
PGA ≥ 3
Diagnosed with moderate-to-severe plaque psoriasis
Exclusion
Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
History of an allergic reaction or known and/or significant sensitivity to study drug
What this trial measures
- Safety and tolerability of ponesimod as measured by reporting of adverse events (AEs)Through study completion, approximately 1 year
Safety will be assessed based on frequency of treatment-emergent adverse events and serious adverse events, and frequency of clinically notable abnormal vital signs, blood chemistry, hematology, urology, and ECGs